Posted by Michael Wonder on 19 Sep 2022
AbbVie secures positive CHMP opinion for risankizumab (Skyrizi) for the treatment of adults with moderate to severe Crohn's disease
19 September 2022 - CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance.
AbbVie today announced the EMA's (CMHP adopted a positive opinion recommending the approval of risankizumab (Skyrizi, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
